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ABSTRACT  Spindle cell carcinoma (SpCC) of the breast is a rare variant of breast 
cancer that has been classified as one of the special types of metaplastic breast carcinoma 
(MBC). MBC consists of a mixture of cells, both epithelial and mesenchymal in origin. 
Immunohistochemical (IHC) analyses of SpCC show positive staining for both epithelial and 
mesenchymal markers. Herein, we report two patients with SpCC of the breast who were 
recently treated at our department. IHC analyses for cytokeratins and other mesenchymal 
markers were useful in making a correct diagnosis of SpCC.
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INTRODUCTION
   Spindle cell carcinoma (SpCC) has been classified 
into a special type of invasive ductal carcinoma 
in the General Rules for Clinical and Pathological 
Recording of Breast Cancer (16th edition)1). SpCC is 
a rare variant of breast cancer. Its incidence has been 
reported to be between 0.1 to 0.5%2. 3). SpCC shows 
some unique pathological and clinical features. As 
pathological features, SpCC is a part of metaplastic 
breast cancer (MBC), and MBC consists of a 
mixture of cells, both epithelial and mesenchymal 
in origin. There are carcinomatous components 
of squamous and spindle cells, and there are 
sarcomatous components with a heterogeneous 
pattern4). As clinical features, rapid growth, a lack 
of lymph node metastasis, triple negative breast 
cancer (TNBC), and a poor prognosis were shown 
in most of the SpCC cases. Here, we report two 
SpCC patients who were recently treated in our 
department.
CASE REPORT
   Case 1: A 52 -year-old female presented with an 
induration in her right breast. She had schizophrenia 
on medication, uterine myoma, and right calyceal 
diverticulum. On physical examination, she had hard 
5cm tumor with redness in her right breast. Axillary 
lymph nodes were not palpable. Mammography was 
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Fig. 1.　Findings of the breast ultrasound examination in 
case 1: A low echoic mass (90×80×50 mm in size) with a 
heterogeneous internal echo texture was observed.
not performed due to a large size tumor. Ultrasound 
examination revealed a low echoic lesion in the 
inner-upper area of her right breast (Fig. 1). Fine-
needle aspiration cytology was performed, and the 
result was suspicious of malignancy. In addition, 
core needle biopsy was performed and SpCC was 
suspected. Modified radical mastectomy and axillary 
lymph node dissection were performed. TNM 
classification for this case was T3N0M0, StageⅡ
B. Adjuvant chemotherapy using tegafur-uracil was 
started after the operation. She had not experienced 
any recurrence as of one year after the operation.
   Case 2: A 66-year-old female presented with a 
tumor in her left breast. She had anemia, type B 
liver cirrhosis on medication, myoma uterus, and 
hemorrhoid. On computed tomography, a 10×7 cm 
tumor with a hematoma inside was observed (Fig. 
2). Ultrasound examination revealed a low echoic 
lesion in the inner-upper area of her left breast. 
Open biopsy was performed and scirrhous or solid-
tubular carcinoma was suspected. Modified radical 
mastectomy and axillary lymph node dissection were 
performed. TNM classification for this case was 
T4cN0M0, Stage Ⅲ B. Pathological diagnosis was 
SpCC. The patient could not receive any adjuvant 
Fig. 2.　Findings of chest computed tomography in case 2: A 
huge breast tumor (10×7 cm in size) with a suspected intra-
tumoral hematoma was observed.
chemotherapy due to liver cirrhosis, but radiation 
therapy was performed on the loco-regional area to 
prevent local recurrence. Unfortunately, lung and 
pleural metastases appeared six months after the 
operation. Chemotherapy including cisplatin for the 
treatment of metastatic diseases was administered 
to the patient based on the suggestions of an expert 
in liver diseases. Regrettably, she died nine months 
after the operation. 
   Summarized IHC results of the two cases are 
shown in Table 1. In addition, representative 
pathological findings are shown in Fig. 3 and 4.
DISCUSSION
   SpCC of the breast is a rare variant of breast 
cancer that has been classified as under the category 
of metaplastic carcinoma5). MBC is a rare poorly 
differentiated breast cancer characterized by the 
coexistence of ductal carcinoma with areas of 
matrix production, spindle cells, and sarcomatous or 
squamous differentiation6). SpCC has characteristics 
of basal-like breast cancer, such as both estrogen 
receptor (ER) and progesterone receptor (PgR) are 
negative, human epidermal growth factor receptor 
(HER) 2 is negative, and the Ki-67 labeling index 
is high. About 70-90% of TNBC is classified into 
basal-like breast cancer. 
   According to a review paper with regard to 35 
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Fig. 3.　Findings of HE and IHC in case 1:
A. Epithelial component (lower), cartilaginous component (left), and spindle cells of spindle cell carcinoma.
B. Prominent nuclear atypia is present both in epithelial and spindle cell components.
C. Epithelial component showing diffuse cytokeratin 14 immunoreactivity. Rare spindle cells expressing cytokeratin 14.
D. Spindle cells with strong immunoreactivity for vimentin. Epithelial component also exhibits some vimentin immunoreactivity. 
Fig. 4.　Findings of HE and IHC in case 2:
A. Spindle cell carcinoma; atypical spindle cells and epithelial component with tubular differentiation.
B.  Cytokeratin AE1/3 (broad-spectrum cytokeratin) immunohistochemistry showing intense reaction in epithelial component and 
weak staining in spindle cells.
C. Vimentin immunoreactivity is present in spindle cells but not in epithelial component.
D. EGFR was positive both in spindle and epithelial components.
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Japanese cases of SpCC of the breast, the average 
age was 52.3 years, about 76% of cases had a tumor 
larger than 3 cm, and most of the SpCC tumors 
had a triple negative phenotype ER-negative, PgR-
negative and HER2-negative2). In spite of large 
tumor sizes, most SpCC cases did not have any 
metastatic lymph nodes2). It has also been reported 
that hematogenous metastases to the lung, brain, 
and/or bone are frequently observed in SpCC 
cases7). The two patients presented here consistently 
had these features. They had large tumors without 
any metastatic lymph node. Their tumors expressed 
neither hormone receptors nor HER2. 
   It is difficult to achieve a definitive diagnosis 
of SpCC before surgery in most SpCC cases. 
Immunohistochemical tests using tumor samples 
obtained by core needle biopsy sometimes facilitate 
a correct diagnosis of SpCC before radical surgery6). 
IHC findings of SpCC showed the positivity of 
epithelial makers such as cytokeratin (CK) 7, pan-
CK, and epithelial membrane antigen (EMA), and 
the positivity of mesenchymal markers such as 
vimentin, nestin, and smooth muscle actin (SMA). 
These finding are mixed in a tumor8).
   According to a comprehensive paper by Carter et 
al. on 29 cases of SpCC of the breast5), the positivity 
rate of CK is high; especially, the positive rate of 
pan-CK (MNF116) and CK14 were 90% or more.
   And CK17  were more than 90%, and the 
positivity rates of p63 and SMA were more than 
50% among the reported cases. On the other hand, 
the positivity rates of AE1/AE3, CAM5.2, and 
EMA were less than 50% among the reported cases. 
Carter et al. suggested that, when the diagnosis of 
SpCC is difficult, an IHC test of a battery of CKs 
including CK14 and CK17 should be performed 
because spindle sarcoma of the breast is very rare. 
Core needle biopsy was performed for case 1, and 
the IHC result indicated that there was a strong 
possibility of SpCC. Although some differences 
were observed in other markers, expressions of 
AE1/AE3 and vimentin were observed in both 
cases.
   Even though lymph node metastasis is not 
observed, sufficient treatment is recommended 
for patients with SpCC because it tends to have 
distant metastases and a poor outcome. Cytotoxic 
chemotherapy including cisplatin is recommended 
as adjuvant therapy for TNBC cases including SpCC 
cases. Preoperative chemotherapy may be an option 
for the treatment of MBC. Takuwa et al. reported 
a case of MBC that showed a positive response to 
Table 1. Immunohistochemical analyses of SpCCs of the breast in two cases 
Case 1 Case 2 
ER － －
ER (%) 0 0
PgR － －
PgR(%) 0 0
HER2/neu － －
HER2 score 1+ 1+
Ki-67 + +
Ki-67(%) 65.8 52.2
Nuclear grade 3 3
AE1/AE3 + +
Vimentin + +
S-100 + －
Desmin + －
CK14 + －
p63 － －
ER; Estrogen receptor, PgR; Progesterone receptor, HER2; Human epidermal growth factor receptor 2, CK14; 
Cytokeratine 14
37Okubo S, et al. : Spindle cell carcinoma of the breast
preoperative chemotherapy. The patient received 
chemotherapy containing cisplatin, docetaxel, 
and doxorubicin before the operation, after the 
chemotherapy, an almost complete response (CR) 
was observed with breast MRI. Partial mastectomy 
was performed, and a nearly pathological CR was 
confirmed. No recurrence has appeared for more 
than two years after the initial chemotherapy in the 
reported case 9). 
   In the latest studies, efficacies of poly adenosine 
diphoshate [ADP] ribose polymerase (PARP) 
inhibitors in patients with TNBC were reported, 
and oral and intravenous PARP inhibitors are under 
development. Their efficacies have been reported as 
not only monotherapy but also in the combination 
with various DNA-damaging agents10). It is known 
that PARP inhibitors inhibit the repair of DNA 
damage and increase apoptosis in cancer cells. Major 
adverse events due to the agents include fatigue, 
nausea, vomiting, and constipation. A phase Ⅱ 
trial comparing the efficacy between chemotherapy 
alone versus chemotherapy plus a PARP inhibitor, 
iniparib, revealed that the latter was significantly 
better than the former in terms of overall survival 
(12.2 versus 7.7 months, respectively, P = 0.01) in 
patients with metastatic TNBC11). On the other hand, 
Okushiba et al. reported an SpCC patient receiving 
multiple operations and radiation, who achieved 
long-term survival of more than ten years after the 
initial operation12). 
   Toumi et al. investigated the outcome of patients 
with MBCs. Their study suggested that patients 
with MBC expressing CK14 tended to have a better 
outcome than those not expressing it4). Interestingly, 
the tumor in case 2 did not express CK14. Lung and 
pleural metastases appeared six months after the 
operation in this case. In contrast, the tumor in case 
1 did express CK14. No distant metastasis has been 
observed for a year after the initial surgery.
   In conclusion, we report two cases of SpCC of the 
breast. SpCC is a rare carcinoma, and most of the 
cases are TNBCs. An IHC test for CKs and others 
is very useful to diagnose SpCC. If the diagnosis of 
SpCC is possible before the operation, preoperative 
chemotherapy should be considered. In addition, if 
diagnosed SpCC is after an operation, aggressive 
postoperative chemotherapy and careful monitoring 
are required.
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